FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016893828> ?p ?o ?g. }

• W2016893828 endingPage "400" @default.
• W2016893828 startingPage "399" @default.
• W2016893828 abstract "1.Understand the unique pharmacology of buprenorphine.2.Start an individual on buprenorphine or rotate to buprenorphine from other opioids. They will understand the potential pitfalls of rotations at high doses.3.Select individuals and clinical scenarios for which buprenorphine could be considered as a first line drug. Buprenorphine has a complex and unique pharmacology which provides some advantages over other potent mu agonists. Twelve reasons for considering buprenorphine as a frontline analgesic for moderate to severe pain are reviewed. Reason 1: Buprenorphine is effective in treating cancer pain. More than 13,000 individuals have been treated with buprenorphine, as reported in various studies, with responses of 80%-90%. Reason 2: Buprenorphine is effective in treating neuropathic pain and is uniquely antihyperalgesic. Reason 3: Buprenorphine treats a broader array of pain phenotypes, broader than other potent mu agonists, and has less analgesic tolerance. Buprenorphine can be combined with other mu agonists such as morphine. Reason 4: Buprenorphine produces less constipation than certain other potent mu agonists and uniquely does not adversely affect the sphincter of Oddi. Reason 5: Buprenorphine has a ceiling effect on respiratory depression but not analgesia. Reason 6: Buprenorphine causes less cognitive impairment than certain other opioids. Reason 7: Buprenorphine is not immunosuppressive like morphine and fentanyl. Reason 8: Buprenorphine does not reduce hypothalamic gonadotropins axis or cause hypogonadism. Reason 9: Buprenorphine does not prolong the QTc interval and is associated with fewer sudden deaths than methadone. Reason 10: Buprenorphine is a safe and effective analgesic for the elderly. Reason 11: Buprenorphine is the one of the safest opioid to use in renal failure and for individuals on dialysis. Reason 12: Withdrawal symptoms are milder with buprenorphine and drug dependence is less. In light of the evidence for its efficacy, safety, versatility, and cost, buprenorphine should be considered as a first line analgesic. This concurrent session will start with a patient presentation followed by a review of the benefits of and some of the problems with using buprenorphine." @default.
• W2016893828 created "2016-06-24" @default.
• W2016893828 creator A5090858955 @default.
• W2016893828 date "2014-02-01" @default.
• W2016893828 modified "2023-10-04" @default.
• W2016893828 title "Why You Should Consider Buprenorphine for Cancer Pain (TH321)" @default.
• W2016893828 doi "https://doi.org/10.1016/j.jpainsymman.2013.12.047" @default.
• W2016893828 hasPublicationYear "2014" @default.
• W2016893828 type Work @default.
• W2016893828 sameAs 2016893828 @default.
• W2016893828 citedByCount "0" @default.
• W2016893828 crossrefType "journal-article" @default.
• W2016893828 hasAuthorship W2016893828A5090858955 @default.
• W2016893828 hasBestOaLocation W20168938281 @default.
• W2016893828 hasConcept C121608353 @default.
• W2016893828 hasConcept C126322002 @default.
• W2016893828 hasConcept C170493617 @default.
• W2016893828 hasConcept C2777389121 @default.
• W2016893828 hasConcept C2778767360 @default.
• W2016893828 hasConcept C2778904085 @default.
• W2016893828 hasConcept C2778949969 @default.
• W2016893828 hasConcept C2780820201 @default.
• W2016893828 hasConcept C2781063702 @default.
• W2016893828 hasConcept C2781072394 @default.
• W2016893828 hasConcept C42219234 @default.
• W2016893828 hasConcept C71924100 @default.
• W2016893828 hasConcept C98274493 @default.
• W2016893828 hasConceptScore W2016893828C121608353 @default.
• W2016893828 hasConceptScore W2016893828C126322002 @default.
• W2016893828 hasConceptScore W2016893828C170493617 @default.
• W2016893828 hasConceptScore W2016893828C2777389121 @default.
• W2016893828 hasConceptScore W2016893828C2778767360 @default.
• W2016893828 hasConceptScore W2016893828C2778904085 @default.
• W2016893828 hasConceptScore W2016893828C2778949969 @default.
• W2016893828 hasConceptScore W2016893828C2780820201 @default.
• W2016893828 hasConceptScore W2016893828C2781063702 @default.
• W2016893828 hasConceptScore W2016893828C2781072394 @default.
• W2016893828 hasConceptScore W2016893828C42219234 @default.
• W2016893828 hasConceptScore W2016893828C71924100 @default.
• W2016893828 hasConceptScore W2016893828C98274493 @default.
• W2016893828 hasIssue "2" @default.
• W2016893828 hasLocation W20168938281 @default.
• W2016893828 hasOpenAccess W2016893828 @default.
• W2016893828 hasPrimaryLocation W20168938281 @default.
• W2016893828 hasRelatedWork W1837738291 @default.
• W2016893828 hasRelatedWork W1992438200 @default.
• W2016893828 hasRelatedWork W2000801346 @default.
• W2016893828 hasRelatedWork W2019316759 @default.
• W2016893828 hasRelatedWork W2037560904 @default.
• W2016893828 hasRelatedWork W2057643659 @default.
• W2016893828 hasRelatedWork W2104912887 @default.
• W2016893828 hasRelatedWork W2993491302 @default.
• W2016893828 hasRelatedWork W4223970543 @default.
• W2016893828 hasRelatedWork W4233846024 @default.
• W2016893828 hasVolume "47" @default.
• W2016893828 isParatext "false" @default.
• W2016893828 isRetracted "false" @default.
• W2016893828 magId "2016893828" @default.
• W2016893828 workType "article" @default.